Kairos goes public with $6M IPO to fund trials of lead cancer drug

With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another clinical-stage drug developer on the other side of the European Society of Medical Oncology annual meeting this weekend.